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T he Influence of Dosage Frequency and Inhalation Device on Therapy 
Compliance in Asthmatic Patients
l.D. Hoftand, M. van Engelshoven, C.P. van Schayck, S.G.M. Cloosterman,
H. FoJgering Dept, o f General Practice and Social Medicine, University of 
Nijmegen, The Netherlands; 1 Dept, o f Pulmonology, Dekkerswald University of 
Nijmegen, The Netherlands
Background: The problem o f non-compliance in daily practice, is still being under­
estimated. It is suggested that an important factor in non-compliance is the dosage 
frequency of a drug. Another factor o f influence could be the kind of inhalation 
device (autohalor/dosisaerosol)
Methods: In a randomised controlled trial with 57 subjects the quotient of used 
and prescribed medication quantity was being measured. Each subject, during six 
weeks, daily used three inhalators (see Table 1). In this way it was possible to com­
pare, within patients, the compliance with different inhalation devices and different 
dosage. A t-test was used to see if there was a difference in mean-compliance 
quotient of aerosol and autohalor. Patients were unaware that the medication was 
weighted before and after the study,
Remits: The mean compliance quotient of the three devices used is 77.63% (SD 
= 24.77; range: 14.77-124.28%).
Table 1, Conipliuncc with prescribed quantity of medication
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Inhalator
1 1 3
Device autohaler autohaler aerosol
Daily doses frequency 2 4 2
Mean compliance quotient 80.69% 69,12% 83.09%
The mean compliance with Inhalator 2 (higher daily doses frequency) is signifi­
cantly lower than the compliance with inhalator I (1 i,5% difference, p = 0.001) 
and inhalator 3 (14,0% difference, p = 0 .001). There appears to be no difference 
between the mean compliance quotient of the dosisaerosol and the autohaler. 
Conclusion: The mean compliance quotient in this study is 78%. Literature shows a 
great variability in compliance, spreading from 4 to 93%. In this study there seems 
to be no influence of the inhalation device irr the compliance. The compliance with 
an. inhalator with a daily doses frequency of four is significantly lower than with 
the inhalators with daily doses frequency of two. A high daily doses frequency 
seems to be of negative influence on compliance,
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Does (he Chronolog A ctua to r Affect the Emitted Dose and Aerosol 
C haracteristics of Tilade M DI?
M. DoJovich, R. Rhem. Dept Medicine, McMaster University, Hamilton, Canada
The Chronolog (Medtrac Technologies, CO) is a microprocessor monitoring de­
vice for metered dose inhalers (MDIs) used to measure patients' compliance with 
taking prescribed medication, logging the date and time of the MDI actuation. The 
current design of the Chronolog requires that the MDI be removed from its native 
actuator mouthpiece and used with the mouthpiece supplied with the Chronolog, 
As the actuator design affects the quality of the spray, it should be confirmed that 
the drug dose delivered per actuation and the aerosol size remain unchanged to 
ensure the same patient dose with the Chronolog. To demonstrate equivalence, 
emitted dose (ED) and particle size were measured for 3 canisters of Tilade ±  
Chronolog. The Anderson 8-stage cascade impactor (ACI) was used as the primary 
sizing method, and the stage contents assayed chemically for nedocrimal sodium 
(NS) using UV absorbance at 255 nm. The Aerosizer time-of-flight sizing system 
(API, MA) was the second sizing method. ED was measured by unit dose sampling 
apparatus for 15 individual actuations per canister. Results: A high variability in 
ED and ACI size distributions was observed between Tilade canisters with their 
native actuators (p <  0,001). With the Chronolog, there was a 9% decrease in 
ED (p = 0.001), a smali (6%) but significant decrease in the MMAD (3.98 ±  
0.19 fim  vs 4.21 ± 0 .1 7  /¿m, p = 0,006) and no change in the GSD. The fine 
particle fraction (FPF) i.e., % particles >  5.8 ¿¿m, was also unchanged. Whether 
the decrease in ED would alter the clinical outcome with use of the Chronolog 
with Tilade is unlikely, but not known. Similarly, the particle size changes were 
small and would be unlikely to alter deposition of NS in the lung when using 
Tilade with the Chronolog. The results with the Aerosizer were the opposite to 
those obtained using the ACI: MMAD increased with the Chronolog (p > 0.001) 
and FPF decreased. Differences may have been due to the need to excessively 
dilute this highly concentrated aerosol (2 mg NS/dose) for accurate sampling with 
the Aerosizer. While the resolution of the Aerosizer is greater than for the ACI, 
the latter technique has the advantage of quantitating the amount of drug per size 
range in absolute terms. As the ACI is currently regarded as the “gold standard”, 
these results should be the primary ones quoted in this comparison. In conclusion, 
it appears that the dose/puff and particle size characteristics of Tilade MDI are 
minimally changed when actuated through the Chronolog and should not affect 
the treatment outcomes for patients using this device.
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Ability of Patients, Nurses and Physicians with Aerosol Inhalation from  M D I. 
A M ulticentric Study
V, Plaza, J. Sane his for the C.E.S.E.A. Group. Hospital Sta. Creu i St. Pan. 
Barcelona, Spain
introduction: The dependence o f successful drug delivery from MDI on the inhala­
tion technique (IT) and the frequent observation of faulty IT in patients (P ) and 
physicians (Ph) are well documented facts. Claims for better instruction of P, nurses 
(N) and Ph have frequently appeared in the related literature for the last 2 decades. 
Objective: To evaluate the correctness of IT in a countiy-wide sample of P, N and 
Ph -all of them familiarized with the use of M D k in order to define adequate 
educational goals for the present time. Methods: Subjects were recruited am ong 
P, N and Ph from 12 health care centers o f  12 Spanish cities spread around the 
country. A total of 1640 volunteers performed a practical demonstration of their IT 
with a placebo MDI in the presence of one of 12 trained observers, who evaluated 
the IT by means o f  a 10 items check list. The score of each item was weighted 
according to its relative importance, to add up a maximum total of 100 points for 
a “correct”’ IT. A difference o f 30 points was considered clinically relevant. IT 
proficiency was correlated with age, years of MDI use, medical specialty (only for 
Ph) and medical center. The table shows the main Results:
Patients Nurses Physicians
Subjects (% of total) 746 (46) 466 (28) 428 (26)
Mean Scorc (SD) 62 (26) 71 (22) 77 (23)
Most Frequent Errors {% subjects):
• Inspir, & firing not coordinated: 42.9 42.5 29.9
t  No post-inspiratory apnea: 56.2 44.2 34.8
% Subjects with 100 Points 8.9 14.6 27.8
Conclusions: Ability to use of MDI in patients and medical personnel is limited, 
Despite the physicians awareness on the IT in the use of MDI, this study show s im­
portant deficiencies, particularly in the most determinant aspects of the inhalation 
maneuver that require deep changes in educational efforts.
* Assoc. Investigators: I. Antepara, A. Basomba, A. Cadahia, N. Cobos, J. Conde, 
F, Duce, E. Losada, J, Martinez, A. Ojeda, L, Sdnchez, V. Sobradillo and  J.L. 
Viejo. Supported by Glaxo-Wellcome, Spain.
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The Efficacy of Salbutamol A dm inistered from a New M etered Dose P o w d er 
Inha le r C om pared with th a t of a M etered  Dose Inhaler with a Spaccr 
O.-P. SeppiilU1, E, Valkila1, G, Kunkel2. 1 Leiras Oy, Turku, Finland;
2 Rudolf-Virchow UniversitHtskiinikum, Berlin, Germany
The aim of the study was to compare the efficacy of one dose (0.1 mg) of 
salbutamol inhaled from a new metered dose powder inhaler (Leiras MDP1) with 
that o f  one dose (0.1 mg) of salbutamol from a conventional metered dose inhaler 
attached to a spacer device (MDI + S).
A new MDP3 has been developed by Leiras Oy to meet the requirements of 
reliable and accurate dosing, high number of respirable particles (<  5.8 m), low 
oropharyngeal deposition o f the drug, and more convenient handling compared 
with those of MDIs connected to a spacer. Leiras MDPl is preloaded w ith  200 
doses of salbutamol powder. The respirable fraction is ca. 50% of the delivered 
dose.
This was a two-day, cross-over, double-blind, double-dummy and placebo- 
controlled multicenter study. Forty-two asthmatic outpatients with the baseline 
FEVj 35-70% of predicted were randomly divided into two groups of equal size. 
On the first day group I inhaled 0.1 mg of salbutamol from an MDPI and placebo 
from an MDI + S, and on the second day placebo form a MDPI and 0.1 mg of 
salbutamol from an MDI + S, With group II the procedure was completed vice 
versa. Pulmonary function (FEVi & R aw) was measured during 6 hours a fte r  drug 
application and compared with predose values.
Thirty-three patients completed the study according to the protocol. The baseline 
FEV i was identical on both study days (1,97 L). With MDI + S the mean increase 
in FEVi was 39% (0.77 L), and with MDPI also 39% (0.77 L). The baseline 
R aw-values were 0.74 kPa * s ■ L-1 and 0.65 kPa * s • L " 1 for MDI +  S and 
MDPI, respectively. The observed decline in Raw was also of similar magnitude; 
52% (0.38 kPa * s • L“ 1) and 47% (0,30 kPa * s ■ L“ 1) with MDI + S and MDPI, 
respectively.
In conclusion, Leiras MDPI appears to be as efficient a device as a conventional 
pressurised MDI attached to a spacer in administering salbutamol in the treatment 
of asthma.
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B ronchodilator Response to Drug Administration from an A ctuator A lone o r 
Spacer Devices
F. Lavorini, G.A, Fontana, M. Chiostri, G. Zanfe r r a r iL ,  Viroli. Sezione di 
Fisiopatohgia Respiratoria, Uni vers it a di Firenze, Verona, Italy; 1 Direzione 
medico Glaxo, Verona, Italy
Spacer devices are extensions to metered-dose inhalers designed to eliminate the 
need for hand-breath co-ordination which reduce the deposition of large aerosol 
particles in the oropharynx. In three groups of asthmatics not trained to  the use 
of MDIs, we evaluated the efficacy of a salbutamol-containing aerosol prepara­
tion administered by a trained staff from either the actuator alone (group 1), or
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